Analysis of varicella vaccine breakthrough rates: Implications for the effectiveness of immunisation programmes

Vaccine

Volumn 18, Issue 25, 2000, Pages 2775-2778

  Brisson, M ^a,b,c   Edmunds, W J ^a,c   Gay, N J ^a   Law, B ^d   De Serres, G ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LAVAL UNIVERSITY   (Canada)

^c CITY UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Efficacy; Vaccine; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CHICKENPOX; CLINICAL TRIAL; HUMAN; MATHEMATICAL MODEL; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; VACCINATION; VARICELLA ZOSTER VIRUS;

EID: 0034659990     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00100-6     Document Type: Article

References (15)

1. Halloran M.E., Struchiner C.J., Longini I.M. Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am. J. Epidemiol. 146:1997;789-803.
2. McLean A.R., Blower S.M. Imperfect vaccines and herd immunity to HIV. Proc. R. Soc. Lond. B. 253:1993;9-13.
3. Halloran M.E., Cochi S.L., Lieu T.A., Wharton M., Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am. J. Epidemiol. 140:1994;81-104.
4. Coudeville L., Paree F., Lebrun T., Sailly J.C. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 17:1999;142-151.
5. Arbeter A.M., Starr S.E., Weibel R.E., Plotkin S.A. Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. J. Pediatr. 100:(6):1982;886-893.
6. Arbeter A.M., Starr S.E., Preblud S.R., Ihara T., Paciorek P.M., Miller D.S., Zelson C.M., Proctor E.A., Plotkin S.A. Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am. J. Dis. Child. 138:(5):1984;434-438.
7. Weibel R.E., Neff B.J., Kuter B.J., Guess H.A., Rothenberger C.A., Fitzgerald A.J., Connor K.A., McLean A.A., Hilleman M.R., Buynak E.B. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310:(22):1984;1409-1415.
8. Weibel R.E., Kuter B.J., Neff B.J., Rothenberger C.A., Fitzgerald A.J., Connor K.A., Morton D., McLean A.A., Scolnick E.M. Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA. 254:(17):1985;2435-2439.
9. Arbeter A.M., Starr S.E., Plotkin S.A. Varicella vaccine studies in healthy children and adults. Pediatrics. 78:(4 Pt 2):1986;748-756.
10. Johnson C., Rome L.P., Stancin T., Kumar M.L. Humoral immunity and clinical reinfections following varicella vaccine in healthy children. Pediatrics. 84:(3):1989;418-421.
11. White C.J., Kuter B.J., Hildebrand C.S., Isganitis K.L., Matthews H., Miller W.J., Provost P.J., Ellis R.W., Gerety R.J., Calandra G.B. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989 [see comments]. Pediatrics. 87:(5):1991;604-610.
12. Kuter B.J., Weibel R.E., Guess H.A., Matthews H., Morton D.H., Neff B.J., Provost P.J., Watson B.A., Starr S.E., Plotkin S.A. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 9:(9):1991;643-647.
13. Clements D.A., Armstrong C.B., Ursano A.M., Moggio M.M., Walter E.B., Wilfert C.M. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr. Infect. Dis. J. 14:(10):1995;874-879.
14. Johnson C.E., Stancin T., Fattlar D., Rome L.P., Kumar M.L. A long-term prospective study of varicella vaccine in healthy children. Pediatrics. 100:(5):1997;761-766.
15. Krause P.R., Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. The Journal of Pediatrics. 127:1995;518-525.